Asia
According to a statement from China’s NHSA, AstraZeneca staff members are suspected of tampering with the genetic testing results of cancer patients in order to defraud medical insurance funds.
Biogen is selling its nearly 50% stake in Samsung Bioepis for $2.3 billion. The move will provide Biogen with additional capital while preparing to cut additional costs through a rumored employee layoff.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Although most of the news about the effectiveness and endurance of COVID-19 vaccines has focused on antibody titers, not as much has been reported on their effect on other parts of the immune system that offer longer-term protection, such as T cells. For that and more, continue reading.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
TScan Therapeutics, Lyell, SQZ Biotech and others secured clearance from the U.S. Food and Drug Administration for their Investigational New Drug Application.
Last week was a relatively quiet week for clinical trial news, particularly around COVID-19. Here’s a look.
For about a century, the way to treat Type 1 diabetes has been via insulin injections. Although research has been conducted on pancreatic islet transplants, it’s a tough nut to crack in terms of organ rejection. There’s been a potential breakthrough in that area involving nanotherapy.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
A checkpoint inhibitor under development from China’s CStone Pharmaceuticals hit the mark in a Phase III non-small cell lung cancer study.
PRESS RELEASES